ATF6 Luciferase Reporter Lentivirus (ATF6 Pathway)

Catalog #
78667
$875 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The ATF6 (Activating Transcription Factor 6) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce most types of mammalian cells, including primary and non-dividing cells. These viruses transduce cells with the firefly luciferase gene driven by multiple copies of an ATF6 response element, located upstream of the minimal TATA promoter. The lentiviruses also transduce a puromycin selection gene (Figure 1). After transduction, the ATF6-mediated response to ER (endoplasmic reticulum) stress can be monitored by measuring luciferase activity.

Figure 1. Schematic of the lenti-vector used to generate the ATF6 luciferase reporter lentivirus.

Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 µl x 2) of lentivirus at a titer >107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Materials Required But Not Supplied
Name Ordering Information
HeLa Cells ATCC #CCL-2
Thaw Medium 1 BPS Bioscience #60187
Tunicamycin Sigma #654380
Clear-bottom, white 96-well tissue culture plate Corning #3610
One-Step™ Luciferase Assay System BPS Bioscience #60690
Luminometer  
Formulation

The lentiviruses were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.

Background

Activating Transcription Factor 6 (ATF6) is a transmembrane transcription factor that responds to endoplasmic reticulum (ER) stress via the unfolded protein response (UPR). In the presence of excess misfolded proteins, the UPR is activated and there is an increase in chaperone expression. ATF6 is one of the three critical proteins of the UPR. In response to ER stress, ATF6 is cleaved, and the cytosolic portion is translocated to the nucleus where it binds to ER stress-response elements on the promoters of target genes, leading to transcription of ER molecular chaperones. Dysfunction in the UPR pathway results in developmental defects, neurodegenerative diseases, and cancer. Strategies targeting ATF6 may prove beneficial for cancer and degenerative disease treatment.